Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it will host a conference call on Thursday 17 April 2008 at 8.30am CET. In this conference call, a leading expert will discuss the medical need and developments in the area of anti-infective drugs as well as the outcome of a recent meeting of the Anti-Infective Drugs Advisory Committee. During that meeting, the committee discussed product development and clinical trial design for both mild/moderate and moderate/severe community acquired pneumonia (CAP). A primary objective for the committee deliberations was to discuss issues relating to clinical trial design.

During the conference call, Arpida will also discuss the clinical data from the ASSIST-1 and ASSIST-2 trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). In addition, the pooled analysis of the clinical data from these two pivotal Phase III trials will be discussed. Part of the data has already been published in earlier press releases, some additional statistical data, not previously published, will also be discussed. All data, as well as the dial-in details, will be made available via a press release on 17 April, prior to the conference call.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been co
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 ... wholesale construction materials, selected SoundConnect to ... their cloud based audio and web conferencing platform ... to support PrimeSource’s employees’ needs. SoundConnect delivers ... , PrimeSource Building Products will be utilizing ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics ... in metabolic disorders, announced today that it has filed ... Securities and Exchange Commission (SEC) relating to the proposed ... The number of shares to be offered and the ... determined. Citigroup and Cowen and Company will ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... ... an antibody designed to block signaling of ErbB3. This is the first of multiple trials ... 2 clinical development program for MM-121. , ... Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that ...
... , ... ... , , , ... ...
... ... ... ... ...
Cached Biology Technology:Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer 2Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer 3BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 2BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 3BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 4BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 5BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 6BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company 7Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California 2Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California 3Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California 4Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California 5
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... 27th Annual Mouse Molecular Genetics Conference from September ... California. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the Genetics Society of ...
(Date:8/28/2014)... Aug. 28, 2014  Privacy Advocate and Senior Staff ... Lynch , joins the lineup of biometric and mobile ... Biometrics UnPlugged Executive Summit in Tampa, Florida ... Previously announced speakers include Steven Rahman, Director, Technology and Strategy ... at Experian. The theme of this year,s event is ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... damage, for example as a result of exposure to ionizing ... damage or program themselves for death, a process called apoptosis. ... as it is remarkable, involving what might be described metaphorically ... DNA packed tightly in the cell nucleus. In intricate ...
... prevalence of a certain form of drug-resistant ... surpassed that of two other common antimicrobial-resistant ... a study conducted by researchers at Hebrew ... long-term care facilities are one of the ...
... offshore drilling last year, federal lawmakers have grappled with the ... allow oil, wave and wind energy development, while sustainably managing ... A new policy paper, published April 10 in Science ... establishing a public trust doctrine for federal waters could be ...
Cached Biology News:CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 2CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 4Study finds multidrug-resistant gram-negative bacteria high in long-term care 2Public trust doctrine could aid management of US oceans 2Public trust doctrine could aid management of US oceans 3
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... is used as an internal standard for ... dilution mass spectrometry. 5-OxoETE is a polyunsaturated ... 5-HETE in human neutrophils. It stimulates cytosolic ... of 2 nM. 5-OxoETE selectively stimulates the ...
... of ten double-stranded RNAs, 10, 20, 30, ... 1,000 base pairs. The dsRNA Marker is ... of double-stranded RNAs. A twenty bp RNA ... adjusted to approximately 25 ng/µl in concentration. ...
Biology Products: